Mersana Therapeutics (MRSN) Stock Forecast & Price Target

$2.04 +0.06 (+3.03%)

(As of 11/22/2024 ET)

Mersana Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 8 Analyst Ratings

Sell
0

Hold
2

Buy
6

Based on 8 Wall Street analysts who have issued ratings for Mersana Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 8 analysts, 2 have given a hold rating, 5 have given a buy rating, and 1 has given a strong buy rating for MRSN.

Consensus Price Target

$6.00
194.12% Upside

According to the 8 analysts' twelve-month price targets for Mersana Therapeutics, the average price target is $6.00. The highest price target for MRSN is $9.00, while the lowest price target for MRSN is $3.00. The average price target represents a forecasted upside of 194.12% from the current price of $2.04.

Get the Latest News and Ratings for MRSN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Mersana Therapeutics and its competitors.

MRSN Analyst Ratings Over Time

Type	Current Forecast 11/24/23 to 11/23/24	1 Month Ago 10/25/23 to 10/24/24	3 Months Ago 8/26/23 to 8/25/24	1 Year Ago 11/24/22 to 11/24/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	5 Buy rating(s)	5 Buy rating(s)	5 Buy rating(s)	0 Buy rating(s)
Hold	2 Hold rating(s)	2 Hold rating(s)	2 Hold rating(s)	6 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$6.00	$6.00	$6.00	$8.00
Forecasted Upside	194.12% Upside	198.51% Upside	284.62% Upside	403.14% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Reduce

“Fed Proof” Your Bank Account with THESE 4 Simple Steps (Ad)

Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.

Learn these 4 simple steps and protect your savings before it’s too late.

MRSN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

MRSN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Mersana Therapeutics Stock vs. The Competition

Type	Mersana Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.88	2.80	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	194.12% Upside	26,880.71% Upside	7.66% Upside
News Sentiment Rating	Positive News See Recent MRSN News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/15/2024	Citigroup 3 of 5 stars		Initiated Coverage	Buy	$5.00	+98.41%
8/14/2024	Robert W. Baird 2 of 5 stars		Lower Target	Neutral ➝ Neutral	$4.00 ➝ $3.00	+122.22%
7/29/2024	Lifesci Capital 2 of 5 stars	C. Zhu Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
3/19/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Underweight ➝ Neutral	$5.00	+2.88%
2/29/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy	$9.00	+85.57%
2/29/2024	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$6.00	+23.71%
Shocking footage from Bill Gates’ $100,000,000,000 AI Bet (Ad) If you missed out on Nvidia, watch this video I just made. Click here for full details.
2/29/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$7.00	+44.33%
2/29/2024	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Nierengarten Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Outperform	$2.00 ➝ $7.00	+44.33%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 05:02 AM ET.

MRSN Forecast - Frequently Asked Questions

: According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for Mersana Therapeutics is $6.00, with a high forecast of $9.00 and a low forecast of $3.00.
: 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mersana Therapeutics in the last twelve months. There are currently 2 hold ratings, 5 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" MRSN shares.
: According to analysts, Mersana Therapeutics's stock has a predicted upside of 194.12% based on their 12-month stock forecasts.
: Mersana Therapeutics has been rated by research analysts at Citigroup in the past 90 days.
: Analysts like Mersana Therapeutics more than other "medical" companies. The consensus rating score for Mersana Therapeutics is 2.88 while the average consensus rating score for "medical" companies is 2.80. Learn more on how MRSN compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Trump Wins… But Elon Says Get Ready to Brace (Ad)

Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy with a heavy hand—building up infrastructure, slapping tariffs on imports, and going all-in on U.S. jobs. But here's the kicker: while Trump's focused on making America stronger, the Washington elite is ready to fight back…

Get ahead of the game with 3 proven strategies to protect your retirement from Washington's next mov

This page (NASDAQ:MRSN) was last updated on 11/23/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mersana Therapeutics (MRSN) Stock Forecast & Price Target